Physiological parameters (cardiac/respiratory events; type and volume of GA drug) · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
The review found no eligible studies for this question.
1 finding from 1 review
Physiological parameters (cardiac/respiratory events; type and volume of GA drug) · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
1 finding from 1 review
Because of substantial clinical and methodological heterogeneity in the studies, we were unable to determine an estimate of effect
2 studies · 148 participants
Very low
Pulmonary embolism · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).
1 finding from 1 review
Recurrent ischaemic or unknown stroke during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes recurrent ischaemic/unknown stroke during treatment period compared with control (very low certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Major extracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Seizure recurrence at 5 years after randomisation · patients with first unprovoked seizure
Immediate treatment leads to lower seizure recurrence at 5 years after randomisation compared with controls (high certainty).
1 finding from 1 review
Five year immediate remission after randomisation · patients with first unprovoked seizure
Immediate treatment leads to higher five‐year immediate remission after randomisation compared with controls (high certainty).
1 finding from 1 review
Five year remission at any time after randomisation · patients with first unprovoked seizure
Immediate treatment showed no clear difference in five‐year remission at any time after randomisation compared with controls (high certainty).
1 finding from 1 review
Seizure recurrence at 1 year after randomisation · patients with first unprovoked seizure
Immediate treatment leads to lower seizure recurrence at 1 year after randomisation compared with controls (high certainty).
1 finding from 1 review
Mortality at the end of the · patients with first unprovoked seizure
Immediate treatment showed no clear difference in mortality at the end of the compared with controls (high certainty).
1 finding from 1 review
Adverse events (control ‐ placebo) · patients with first unprovoked seizure
Immediate treatment probably leads to higher adverse events (control ‐ placebo) compared with controls (moderate certainty).
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Treatment satisfaction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Parasympathomimetic drugs (choline esters, cholinesterase inhibitors) vs No treatment
Outcome not reported · Patients with radiation-induced salivary gland dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Total (all‐cause) mortality · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in total (all‐cause) mortality compared with placebo/no antifungal/any other antifungal (moderate certainty).
1 finding from 1 review
Proven invasive fungal infection · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… may leads to lower proven invasive fungal infection compared with placebo/no antifungal/any other antifungal (low certainty).
1 finding from 1 review
Superficial fungal infection · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in superficial fungal infection compared with placebo/no antifungal/any other antifungal (low certainty).
1 finding from 1 review
Fungal colonization · preventing fungal infections in non‐neutropenic critically ill patients
Untargeted antifungal treatment with any antifungal drug (systemic… may leads to lower fungal colonization compared with placebo/no antifungal/any other antifungal (low certainty).
1 finding from 1 review